Please login to the form below

Real-world studies

by Bill Row

How to ensure digital content achieves the right dialogue

By Diane Wass

By Gretchen Goller and Valerie Legrand

To develop sustainable business models that establish value ‘beyond the pill’, collaboration is the best way forward

Accelerating diagnosis in rare disease

Biopharmaceutical companies can drive effective partnerships and improve outcomes for all stakeholders and patients in the area of rare disease.
Accelerating innovation

Ipsen’s Alexandre Lebeaut on the French firm’s oncology plans, global focus and R&D approach
Janssen’s quest to prevent diseases taking hold

Johan van Hoof, general manager of Janssen Vaccines & Prevention, on 'recalibrating' public understanding of illness
Opening up innovation

Paul-Peter Tak on GlaxoSmithKline’s R&D strategy and the pivotal role of immunology
Transformational technology

Big data, the cloud and the value of insights
Can biosimilars live up to the hype?

Carol Lynch, chair of the European Generic Medicines Association, wants new biosimilars therapies to become routine

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Add my company

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Report: Customer experience, shaping digital healthcare: In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Encouraging signs in biomarker R&D: The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it: What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...